Ramli Iman, Cheriet Thamere, Posadino Anna Maria, Giordo Roberta, Zayed Hatem, Eid Ali H, Pintus Gianfranco
Laboratory of Applied Biochemistry, Faculté des sciences de la nature et de la vie, Université Frères Mentouri Constantine 1, 25000 Constantine, Algeria.
Unité de Valorisation des Ressources Naturelles, Molécules Bioactives et Analyses Physicochimiques et Biologiques, Université des Frères MentouriConstantine, 25000 Constantine, Algeria.
Front Biosci (Landmark Ed). 2023 Sep 14;28(9):198. doi: 10.31083/j.fbl2809198.
Pulmonary fibrosis (PF) is a feared component in over 200 interstitial pulmonary diseases, which are characterized by increased alveolar wall thickness, excessive scarring, and aberrant extracellular matrix restructuring that, ultimately, affect lung compliance and capacity. As a result of its broad range of biological activities, including antioxidant, anti-inflammatory, antiapoptotic, and many others, resveratrol has been shown to be an effective treatment for respiratory system diseases, including interstitial lung disease, infectious diseases, and lung cancer. This work reviews the known molecular therapeutic targets of resveratrol and its potential mechanisms of action in attenuating PF in respiratory diseases, including cancer, COVID-19, interstitial lung diseases (ILDs) of known etiologies, idiopathic interstitial pneumonia, and ILDs associated with systemic disorders, such as rheumatoid arthritis, systemic sclerosis, Schrödinger's syndrome, systemic lupus erythematosus, and pulmonary hypertension. The current issues and controversies related to the possible use of resveratrol as a pharmaceutical drug or supplement are also discussed.
肺纤维化（PF）是200多种间质性肺疾病中令人担忧的一个组成部分，这些疾病的特征是肺泡壁厚度增加、瘢痕形成过多以及细胞外基质异常重构，最终影响肺顺应性和容量。由于白藜芦醇具有广泛的生物学活性，包括抗氧化、抗炎、抗凋亡等多种活性，它已被证明是治疗呼吸系统疾病的有效药物，这些疾病包括间质性肺病、传染病和肺癌。本文综述了白藜芦醇已知的分子治疗靶点及其在减轻包括癌症、COVID-19、已知病因的间质性肺病（ILDs）、特发性间质性肺炎以及与全身性疾病（如类风湿性关节炎、系统性硬化症、薛定谔综合征、系统性红斑狼疮和肺动脉高压）相关的ILDs等呼吸系统疾病中的PF的潜在作用机制。还讨论了与白藜芦醇作为药物或补充剂可能的用途相关的当前问题和争议。
